The data presented herein indicate that PRG4 has the potential to enhance the anti-tumor efficacy of regorafenib in the treatment of hepatocellular carcinoma (HCC), without necessitating dose escalation and thereby mitigating the risk of associated side effects. The gene discussed is PRG4; the disease is neoplasm.